Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafrate AJ.

J Thorac Oncol. 2011 May;6(5):942-6. doi: 10.1097/JTO.0b013e31821528d3.

3.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
4.

High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.

Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC.

J Thorac Oncol. 2014 May;9(5):646-53. doi: 10.1097/JTO.0000000000000145.

5.

Crizotinib in the management of advanced-stage non-small-cell lung cancer.

Loong HH, Mok K, Leung LK, Mok TS.

Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314. Review.

PMID:
25757678
6.

Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.

Jänne PA, Shaw AT, Camidge DR, Giaccone G, Shreeve SM, Tang Y, Goldberg Z, Martini JF, Xu H, James LP, Solomon BJ.

J Thorac Oncol. 2016 May;11(5):737-47. doi: 10.1016/j.jtho.2016.01.022. Epub 2016 Feb 18.

7.

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ.

Oncologist. 2012;17(11):1351-75. doi: 10.1634/theoncologist.2012-0311. Epub 2012 Sep 18. Review.

8.

Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.

Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ.

J Thorac Oncol. 2010 Dec;5(12):2044-6. doi: 10.1097/JTO.0b013e318200f9ff. No abstract available.

9.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
10.

Crizotinib for the treatment of patients with advanced non-small cell lung cancer.

Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A.

Drugs Today (Barc). 2012 Apr;48(4):271-82. doi: 10.1358/dot.2012.48.4.1769835. Review.

PMID:
22536569
11.

Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.

Lu S, Azada MC, Ou SH.

Lung Cancer. 2015 Feb;87(2):207-9. doi: 10.1016/j.lungcan.2014.12.011. Epub 2014 Dec 19.

PMID:
25558789
12.

ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?

Toyokawa G, Seto T.

Clin Lung Cancer. 2014 Sep;15(5):313-9. doi: 10.1016/j.cllc.2014.05.001. Epub 2014 Jun 2. Review.

PMID:
24984564
13.

Crizotinib in the treatment of non--small-cell lung cancer.

Rothschild SI, Gautschi O.

Clin Lung Cancer. 2013 Sep;14(5):473-80. doi: 10.1016/j.cllc.2013.04.006. Epub 2013 Jun 20. Review.

PMID:
23790969
14.

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.

Lung Cancer. 2015 Feb;87(2):89-95. doi: 10.1016/j.lungcan.2014.12.010. Epub 2014 Dec 18. Review.

15.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators.

N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582.

16.

Crizotinib resistance: implications for therapeutic strategies.

Dagogo-Jack I, Shaw AT.

Ann Oncol. 2016 Sep;27 Suppl 3:iii42-iii50. doi: 10.1093/annonc/mdw305. Review.

17.

Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.

Kinoshita Y, Koga Y, Sakamoto A, Hidaka K.

BMJ Case Rep. 2013 Sep 10;2013. pii: bcr-2013-200867. doi: 10.1136/bcr-2013-200867.

18.

Treatment and detection of ALK-rearranged NSCLC.

Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.

Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12. Review.

PMID:
23769207
19.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ.

N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.

20.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065

Supplemental Content

Support Center